Behçet uveitis can be treated with a combination of immunomodulatory drugs and glucocorticoids. However, the optimal immunomodulator for this combination therapy remains unclear. A randomized, open-label, head-to-head trial has now compared the efficacy and safety of ciclosporin, interferon alfa-2a and adalimumab in combination with ongoing glucocorticoid treatment for the prevention of uveitis relapse in patients with Behçet syndrome.

The single-centre study enrolled 270 individuals with severe Behçet syndrome and uveitis who were being treated with glucocorticoids and were naive to anti-TNF therapy. The annualized rate of uveitis relapse was 1.84 (95% CI 1.40–2.44) with ciclosporin plus glucocorticoids, 1.44 (1.10–1.89) with interferon alfa-2a plus glucocorticoids and 0.95 (0.64–1.40) with adalimumab plus glucocorticoids.